Vivek Subbiah, MD
Department of Investigational Cancer Therapeutics, The University of MD Anderson Cancer Center, Houston, USA
Dr. Vivek Subbiah is a Clinical trialist and Physician Investigator at Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center which is the largest oncology drug development unit in the world. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a specialist interest in precision oncology, anti-body drug conjugates, radio-pharmaceuticals, immunoconjugates and basket trials.
His main research focuses on the first-in-human development of molecularly targeted agents and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. He is Principal Investigator for several clinical trials evaluating novel strategies using anti-body drug conjugates, as well as the blockade of signaling pathways, with a focus on BRAF inhibitors in non-melanoma tumors, RET and mTOR pathways.
Dr. Subbiah is on the editorial board of PLOS One, Scientific Reports and Pan-cancer panel with Collabrx. He has published widely in peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology and JAMA Oncology. In addition, by using cutting-edge molecular profiling and the large portfolio of targeted drugs, he is positioning to lead the way in identifying new treatments for the atypical cancers that these young people develop. He is providing an unmatched opportunity to fulfill an unmet need in treating AYA who suffer from cancer. His research interests include adolescent and young adult oncology, phase 1 trials – drug development (molecularly targeted therapy, radiopharmaceutical studies and immunotherapeutic studies), and clinical trials with molecularly targeted agents in targetable rare diseases (eg, translocation positive sarcomas, NF1, NF2). He also has a passion for N=1 studies in cancer patients that have dramatic responses to therapies by in depth analysis through next generation sequencing, morphoproteomics, and other cutting edge methods for analysis of response/ resistance mechanisms.